SERODOPA THERAPEUTICS INC

Biotech · Private

A novel opioid antagonist molecule designed to reverse fentanyl-induced respiratory depression more effectively and rapidly than naloxone

Grants
$2.9M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · NX90: A Treatment for Overdose Caused by High Potency Opioids$1,539,426
Federal grantDepartment of Health and Human Services · Phase II · NX90: A Treatment for Overdose Caused by High Potency Opioids$1,407,382
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2752LUMEN BIOSCIENCE, INC.—$50M
2753Bicycle Therapeutics——
2754Curevo Vaccine——
2755SERODOPA THERAPEUTICS INC——
2756CASTAG BIOSCIENCES, INC.——
2757VAXFORM, LLC——
2758LINNAEUS BIOSCIENCE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.